Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemo brain under the microscope: largest study yet launched

NCT ID NCT01382082

Knowledge-focused Sponsor: University of Rochester NCORP Research Base Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks over 1,400 breast cancer and lymphoma patients to see how chemotherapy affects memory, attention, and thinking skills. Researchers test patients before, right after, and up to years after treatment. The goal is to learn who is most at risk for 'chemo brain' and why, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,432 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2011

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

During enrollment, the groups will be balanced on age and gender. Controls of the same age and gender as the subject receiving chemotherapy will be enrolled at the same time.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects Receiving Chemotherapy: * Have a diagnosis of invasive breast cancer (stage I-IIIC) or intermediate or high-grade\* lymphoma (\*defined by the treating physician) * Be scheduled to begin a course of chemotherapy * Oral chemotherapy is acceptable * Previous or concurrent treatment with hormones or biological response modifiers is acceptable. (Subjects receiving biological response modifiers only are not eligible). * Be chemotherapy naïve * Life expectancy greater than 10 months * Be able to speak and read English * Give written informed consent Inclusion Criteria, Controls: * Must be the same gender as the subject receiving chemotherapy * Must be within 5 years of the age of the subject receiving chemotherapy * Life expectancy greater than 10 months * Be able to speak and read English * Give written informed consent * Must be willing to participate in the study for the entire period Inclusion Criteria, Long-Term Followup Study: * Must be a subject who had breast cancer, or control who was paired with that subject with breast cancer, who provided CANTAB data at any time-point during assessments 1 through 3. Exclusion Criteria: Subjects Receiving Chemotherapy: * Must not be currently hospitalized or have been hospitalized within the last year for a psychiatric illness * Must not be diagnosed with a neurodegenerative disease * Must not have primary central nervous system (CNS) disease * Must not have received chemotherapy in the past * Must not be scheduled to receive concurrent radiation treatment * Must not have metastatic disease (subjects with breast cancer) * Must not be pregnant * Must not be colorblind Exclusion Criteria, Controls: * Must not be currently hospitalized or have been hospitalized within the last year for a psychiatric illness * Must not be diagnosed with a neurodegenerative disease * Must not have primary CNS disease * Must not have been diagnosed with cancer or previously have received chemotherapy * Must not be pregnant or plan on becoming pregnant during the study period * Must not be colorblind Exclusion Criteria, Long-Term Followup Study: * Must not have dementia or any severe neurodegenerative disease that would prohibit the ability to complete cognitive testing. * Must not be colorblind

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Lymphoma

Contacts and locations

Locations

  • Aurora NCORP

    Milwaukee, Wisconsin, 53226, United States

  • CCOP - Nevada Cancer Research Foundation

    Las Vegas, Nevada, 89106, United States

  • CRCWM

    Grand Rapids, Michigan, 49503, United States

  • Cancer Research Consortium of West Michigan

    Grand Rapids, Michigan, 49503, United States

  • Columbus

    Columbus, Ohio, 43215, United States

  • Columbus NCORP

    Columbus, Ohio, 43215, United States

  • Dayton

    Dayton, Ohio, 45459, United States

  • Dayton Community Oncology Program

    Dayton, Ohio, 45420, United States

  • Delaware/Christiana Care NCORP

    Newark, Delaware, 19713, United States

  • Delaware/Christiana Care NCORP (CHRISTIANA)

    Newark, Delaware, 19718, United States

  • Gulf South MU-NCORP

    New Orleans, Louisiana, 70112, United States

  • Heartland

    Decatur, Illinois, 62526, United States

  • Hem Onc CNY

    East Syracuse, New York, 13057, United States

  • Kansas City

    Rochester, New York, 14642, United States

  • Kansas City Clinical Oncology Program

    Prairie Village, Kansas, 66208, United States

  • Metro Minnesota Community Oncology Research Consortium

    Saint Louis Park, Minnesota, 55416, United States

  • Metro Minnesota NCORP

    Minneapolis, Minnesota, 55426, United States

  • NCORP of the Carolinas

    Greenville, South Carolina, 29605, United States

  • Nevada

    Las Vegas, Nevada, 89106, United States

  • Northwest (Virginia Mason)

    Seattle, Washington, 98101, United States

  • Novant Health Cancer Institute - Kernersville

    Winston-Salem, North Carolina, 27103, United States

  • PCRC

    Portland, Oregon, 97213, United States

  • Pacific Cancer Research Consortium Ncorp

    Portland, Oregon, 97213, United States

  • Southeast Clinical Oncology Research Program

    Winston-Salem, North Carolina, 27104, United States

  • University of Rochester Cancer Center

    Rochester, New York, 14642, United States

  • Upstate Carolina

    Spartanburg, South Carolina, 29303, United States

  • Wichita

    Wichita, Kansas, 67214, United States

  • Wichita NCORP

    Wichita, Kansas, 67214, United States

  • Wisconsin NCORP

    Marshfield, Wisconsin, 54449, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.